Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134(16): 818-822
DOI: 10.1055/s-0029-1220237
DOI: 10.1055/s-0029-1220237
Übersicht | Review article
Kardiologie, Pneumologie
© Georg Thieme Verlag KG Stuttgart · New York
Kardiopulmonale Interaktionen: Kardiovaskuläre Erkrankungen und COPD
Cardiopulmonary interactions: Cardiovascular diseases and chronic obstructive pulmonary diseaseFurther Information
Publication History
eingereicht: 6.3.2009
akzeptiert: 2.4.2009
Publication Date:
07 April 2009 (online)
Schlüsselwörter
chronisch obstruktive Lungenerkrankung - COPD - kardiovaskuläre Erkrankungen - Herzinsuffizienz - Rauchen - Komorbidität
Keywords
chronic obstructive pulmonary disease - COPD - cardiovascular diseases - chronic heart failure - smoking - comorbidity
Literatur
- 1 Alexeeff S E, litonjua A A, Sparrow D. et al . Statin use reduces decline in lung function. VA Normative Aging Study. Am J Respir Crit Care Med. 2007; 176 742-47
- 2 Augusti A, Thomas A. Neff Lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc. 2006; 3 478-81
- 3 Baigent C, Keech A, Kearney P M. et al . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005; 366 1267-78
- 4 Boyd C M, Darer J, Boult C. et al . Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005; 294 716-24
- 5 Bozkanat E, Tozkoparan E, Baysan O. et al . The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Intern Med Res. 2005; 33 537-544
- 6 Calverly P MA, Anderson J A, Celli B. et al . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356 775-89
- 7 Cazzola M, Imperatore F, Salzillo A. et al . Cardiac effects of Formoterol and Salmeterol in Patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998; 114 411-415
- 8 Chan E D, King T E. Pulmonary disease induced by cardiovascular drugs. 2007 www.uptodate.com
- 9 Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991; 121 1244-63
- 10 European Society of Cardiology, Heart Failure Association of the ESC, European Society of Intensive Care Medicine et al . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008; 10 933-989
- 11 Fabbri L M, Luppi F, Beghe B, Rabe K F. Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31 204-12
- 12 Fabbri L M, Rabe K F. From COPD to chronic systemic inflammatory syndrome?. Lancet. 2007; 370 797-99
- 13 Funk G C, Lang I, Schenk P. et al . Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. Chest. 2008; 133 1354-59
- 14 Gissi-HF, Tavazzi L, Maggioni A P. Investigators, et al . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 1231-39
- 15 Groenwegen K H, Postma D S, Hop W CJ. et al . Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008; 133 350-57
- 16 Hansson G K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352 1685-95
- 17 Hawkins N M, Petrie M C, Jhund P S. et al . Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009; 11 130-39
- 18 Hole D J, Watt G C, Davey-Smith G. et al . Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996; 313 711-15
- 19 Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J. 2005; 25 634-39
- 20 Ito K, Barnes P J. COPD as a disease of accelerated lung aging. Chest. 2009; 135 173-80
- 21 Kjekshus J, Apetrei E, Barrios V. et al . Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357 2248-61
- 22 Lee S H, Goswami S, Grudo A. et al . Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007; 13 567-69
- 23 Le J emtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007; 49 171-80
- 24 Liuzzo G, Biasucci L M, Gallimore J R. et al . The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331 417-424
- 25 Macie C, Wooldrage K, Manfreda J, Anthonisen N R. Inhaled corticosteroids and mortality in COPD. Chest. 2006; 130 640-46
- 26 Nagaya N, Nishikimi T, Uematsu M. et al . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102 865-870
- 27 Pai J K, Pischon T, Ma J. et al . Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351 2599-2610
- 28 Rabe K F, Hurd S, Anzueto A, Barnes P J. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176 532-555
- 29 Rutten F H, Cramer M M, Grobbee D E. Unrecognized heart failure in eldery patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005; 26 1887-94
- 30 Salpeter S R, Ormiston T, Salpeter E E. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest. 2004; 125 2309-21
- 31 Salpeter S R, Ormiston T, Salpeter E E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002 2: CD003566
- 32 Sevenoaks M J, Stockley R A. Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype?. Respir Res. 2006; 7 70
- 33 Silver M A, Maisel A, Yancy C W. et al . BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease. Congest Heart Fail. 2004; 10 1-30
- 34 Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: role of comorbidities. Eur Respir J. 2006; 28 1245-57
- 35 Singh S, Loke Y, Furberg C. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA. 2008; 300 1439-50
- 36 Soyseth V, Brekke P H, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29 279-83
- 37 Suissa S, Assimes T, Ernst P. Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003; 58 43-46
- 38 Takabatake N, Nakamura H, Abe S. et al . The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161 1179-84
- 39 Tashkin D P, Celli B, Senn S. et al . A 4-year trial of Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 358 1543-54
- 40 The CAPRICORN investigators . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357 1385-90
- 41 The CIBIS II investigators and committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353 9-13
- 42 van der Woude H, Zaagsma J, Postma D S. et al . Detrimental effects of β-blockers in COPD. Chest. 2005; 127 818-24
- 43 Walter R E, Wilk J B, Larson M G. et al . Systemic inflammation and COPD. The Framingham Heart Study. Chest. 2008; 133 19-25
- 44 Watz H, Waschki B, Boehme C. et al . Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity. Am J Resp Crit Care Med. 2008; 177 743-51
Dr. med. Christian Ukena
Klinik für Innere Medizin III, Kardiologie,
Angiologie und Internistische Intensivmedizin, Universitätskliniken
des Saarlandes
Kirrberger Straße
66421
Homburg/Saar
Email: Christian.ukena@uks.eu